Why the study?
Patients with AF face ongoing thrombotic risks manifesting as silent cerebral embolisms after left atrial appendage occlusion, but strong evidence for half-dose anticoagulation is lacking.
Does half-dose anticoagulation reduce the incidence of silent cerebral embolisms in patients with atrial fibrillation after left atrial appendage occlusion compared to standard antithrombotic therapy?
Does half-dose anticoagulation reduce the incidence of silent cerebral embolisms in patients with atrial fibrillation after left atrial appendage occlusion compared to standard antithrombotic therapy?
The HALO-SCE trial will determine if half-dose anticoagulation is superior to standard antithrombotic therapy for preventing silent cerebral embolisms and protecting cognitive function after left atrial appendage occlusion.
Answers are grounded in this paper and cite their sources.
May optimize post-LAAO antithrombotic regimens; extends RCT evidence on silent embolism and cognitive outcomes in AF.
INTRODUCTION: Patients with atrial fibrillation (AF) continue to face thrombotic risks even after the left atrial appendages have been occluded, which may manifest as silent cerebral embolisms (SCEs). Half-dose anticoagulation (Hd-OAC) is a pathophysiologically more reasonable therapy in addressing this issue than antithrombotic therapy, but it still lacks strong evidence. METHODS: The trial (NCT05671276) is a multicenter, randomized controlled trial comparing the efficacy of two antithrombotic strategies (Hd-OAC therapy vs. standard antithrombotic therapy) in AF patients after left atrial appendage occlusion (LAAO). The primary endpoint is the incidence of newly detected SCEs on any magnetic resonance imaging conducted during the follow-up period. The secondary endpoints are: (1) more than two new SCEs during the follow-up, their size, and distribution; (2) cognitive function, and (3) a composite endpoint of all-cause mortality, clinical thromboembolic events, and major bleeding events. Follow-up is scheduled at 90 ± 15 days, 180 ± 15 days, and 365 ± 15 days after LAAO. CONCLUSIONS: This trial aimed to determine whether Hd-OAC therapy can reduce the incidence of SCE and protect cognitive function in patients who have successfully undergone LAAO, compared to standard antithrombotic therapy.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: